Table 1.
Model input values, ranges for sensitivity analyses, distributions, and data sources.
Fig 1.
MDMA-assisted therapy costs by component; Total: $11,537 per patient.
Table 2.
Net present costs, health benefits and cost-effectiveness results for 30, 10, 3.8 and 1-year analytic time horizons for 1,000 patients.
Fig 2.
Net cost (neg = savings) of MDMA-AT over 30-year analytic time horizon; for 1,000 patients using input variables across the range of values shown in Table 1; Inputs ranked by effect on output mean.
Fig 3.
Multivariable sensitivity analysis on net cost (neg. = savings).
10,000 iterations of a Monte Carlo simulation assuming PTSD progression risk varied from 0.05 to 0.15 annually in a uniform distribution in patients receiving MDMA-AT; 1,000 patients over a 30-year analytic horizon.
Table 3.
Incremental costs, QALYs and cost-effectiveness: Phase 3 vs phase 2 regimen for 1,000 patients; 1, 5, 10, and 30-year analytic time horizons for 1,000 patients.